Table 3.

Immunogenicity against different mumps genotypes and ELISA antibodies.

Mumps NT against	JVC-001 (n = 49)	MR+Mumps (n = 50)
Genotype A
Seroconversion rate	41/48 (85.4%, [72.2–93.9%])	28/50 (56.0%, [41.3–70.0%])
GMT at Day 42	19.9, [95% CI: 13.2–29.9]	5.8 [95% CI: 4.0–8.4]
Genotype B
Seroconversion rate	41/48 (85.4%, [72.2–93.9%])	33/50 (66.0%, [51.2–78.8%])
GMT at Day 42	15.8, [95% CI: 10.9–22.8]	6.8, [95% CI: 4.8–9.6]
Genotype G
Seroconversion rate	37/48 (77.1%, [62.7–88.0%])	32/49 (65.3%, [50.4–78.3%])
GMT at Day 42	12.5, [95% CI: 8.6–18.3]	7.1, [95% CI: 5.0–10.1]
Genotype D
Seroconversion rate	39/43 (90.7%, [77.9−97.4%])	46/48 (95.8%, [85.8–99.5%])
Seroresponse rate	38/43 (88.4%, [74.9–96.1%])	42/48 (87.5%, [74.8–95.3%])
GMT at Day 42	32.1, [95% CI: 19.6–52.4]	31.4, [95% CI:19.6–50.5]
Mumps ELISA	JVC-001 (n = 49)	MR+Mumps (n = 50)
Seroconversion rate	45/48 (93.8%, [82.8–98.7%])	46/49 (93.9%, [83.1–98.7%])
GMT at Day 42	1745.0, [95% CI: 1250.2–2435.5]	1400.4, [95% CI: 964.6–2033.0]

Note: See immunological assessment section for the definition of seroconversion/seroresponse rate. Population parameters of each seroconversion/seroresponse rate were calculated based on each definition with each cut-off value in pre-immunization. Subjects whose assay data was failed to obtain were also eliminated from the calculation.